ReviewAntibiotics (Basel, Switzerland)2023
Evaluation of Antibiotic Resistance Mechanisms in Gram-Negative Bacteria.
Review in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
112 citing papers in PubMed, 188 citations in OpenAlex.
- Plasma and intrapulmonary pharmacokinetics of ceftibuten and ledaborbactam in healthy male and female adults.Antimicrobial agents and chemotherapy · 2026Trial
- Pharmacokinetics, safety, and tolerability of HRS-8427, a novel anti-carbapenem-resistant cephalosporin, in healthy subjects.Antimicrobial agents and chemotherapy · 2026Trial
- Intrapulmonary penetration and pharmacokinetics of siderophore cephalosporin HRS-8427 injection in Chinese healthy subjects.Antimicrobial agents and chemotherapy · 2025Trial
- Safety and pharmacokinetics of single and multiple doses of ledaborbactam etzadroxil with or without ceftibuten in healthy volunteers.Antimicrobial agents and chemotherapy · 2025Trial
- Antimicrobial and Antibiofilm Activity of an Endophytic Fungus, Daldinia sp. Isolated From Avicennia officinalis.MicrobiologyOpen · 2026Article
- Nano-antimicrobial peptides (Nano-AMPs) to combat resistant gram-negative bacteria.Drug delivery and translational research · 2026Review
- Comparative Analysis of Phenolic Acid Profiles, Antioxidant Capacity, and Antimicrobial Activity of Honeys from Different Botanical and Geographical Origins.International journal of molecular sciences · 2026Article
- Designing the Next Generation of Antibiotics: Structure, SAR, and Strategy in Medicinal Chemistry (2000-2025).Medicinal research reviews · 2026Review
- PEPTiGEN: a tool for mining antimicrobial resistance PEPTides using GENe data of public available repositories.Bioinformatics (Oxford, England) · 2026Article
- Integrated Molecular Docking and Molecular Dynamics Approaches Reveal Potential Antimicrobial Metabolites from Echinoderms,Biology · 2026Article
- Lyophilization Prior to Homogenisation and Extraction Increases Membrane Protein Detection in Gram-Negative Bacterial Proteomic Analyses.Proteomes · 2026Article
- Evaluation of Short Versus Long Course of Tobramycin Combined with Piperacillin/Tazobactam Against Antibiotic-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Antimicrobial Peptides and ESKAPEE Pathogens: A New Frontier in the Fight Against Antimicrobial Resistance.Probiotics and antimicrobial proteins · 2026Review
- Molecular detection of extended-spectrum β-Lactamase genes in multi-drug-resistant bacteria isolated from drinking water supply and surface water systems in Addis Ababa, Ethiopia.BMC microbiology · 2026Article
- Artificial Intelligence in Bacteriophage Science: A Comprehensive Narrative Review of Applications, Challenges, and Translational Opportunities.Antibiotics (Basel, Switzerland) · 2026Review
- Exploring the Antimicrobial Efficacy of Mesenchymal Stem Cell Secretome Against Klebsiella pneumoniae in Urinary Tract Infections.Clinical and translational science · 2026Article
- First comprehensive whole genome sequencing report of a multidrug-resistantNew microbes and new infections · 2026Article
- Antimicrobial resistance in veterinary medicine: Mechanisms, regulation and control strategies.Veterinarni medicina · 2026Review
- Beyond β-Lactams: Defining the Role of Eravacycline in Multidrug-Resistant and Metallo-β-Lactamase-Producing Infections.Antibiotics (Basel, Switzerland) · 2026Review
- Long-Term Trends in Antimicrobial Resistance Among Gram-Negative Clinical Isolates at Mubarak Al-Kabeer Hospital, Kuwait (2007-2022).Antibiotics (Basel, Switzerland) · 2026Article
52 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug-resistant Gram-negative bacterial infections are exponentially increasing, posing one of the most urgent global healthcare and economic threats. Due to the lack of new therapies, the World Health Organization classified these bacterial species as priority pathogens in 2017, known as ESKAPE pathogens. This classification emphasizes the need for urgent research and development of novel targeted therapies. The majority of these priority pathogens are Gram-negative species, which possess a structurally dynamic cell envelope enabling them to resist multiple antibiotics, thereby leading to increased mortality rates. Despite 6 years having passed since the WHO classification, the progress in generating new treatment ideas has not been sufficient, and antimicrobial resistance continues to escalate, acting as a global ticking time bomb. Numerous efforts and strategies have been employed to combat the rising levels of antibiotic resistance by targeting specific resistance mechanisms. These mechanisms include antibiotic inactivating/modifying enzymes, outer membrane porin remodelling, enhanced efflux pump action, and alteration of antibiotic target sites. Some strategies have demonstrated clinical promise, such as the utilization of beta-lactamase inhibitors as antibiotic adjuvants, as well as recent advancements in machine-based learning employing artificial intelligence to facilitate the production of novel narrow-spectrum antibiotics. However, further research into an enhanced understanding of the precise mechanisms by which antibiotic resistance occurs, specifically tailored to each bacterial species, could pave the way for exploring narrow-spectrum targeted therapies. This review aims to introduce the key features of Gram-negative bacteria and their current treatment approaches, summarizing the major antibiotic resistance mechanisms with a focus on
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.